Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ovid Therapeutics Inc (NQ: OVID ) 1.090 -0.010 (-0.91%) Streaming Delayed Price Updated: 11:29 AM EDT, Oct 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 11,469 Open 1.070 Bid (Size) 1.080 (14) Ask (Size) 1.100 (24) Prev. Close 1.100 Today's Range 1.070 - 1.120 52wk Range 0.6800 - 4.100 Shares Outstanding 70,417,345 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin September 26, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth September 11, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Performance YTD -67.17% -67.17% 1 Month +1.87% +1.87% 3 Month +24.71% +24.71% 6 Month -65.72% -65.72% 1 Year -70.86% -70.86% More News Read More Ovid Therapeutics to Present at Upcoming September Investor Conferences September 04, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts August 19, 2024 Via Benzinga The Latest Analyst Ratings For Ovid Therapeutics July 26, 2024 Via Benzinga Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts June 18, 2024 Via Benzinga OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 13, 2024 Via InvestorPlace Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results August 13, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer August 08, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm August 01, 2024 From The Schall Law Firm Via Business Wire Ovid Therapeutics to Present at Upcoming August Investor Conferences July 30, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists July 23, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire 7 Sorry Biotech Stocks Set to Make Investors Sad July 22, 2024 Via InvestorPlace eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures July 10, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations July 01, 2024 From Ovid Therapeutics Inc. Via GlobeNewswire Nasdaq Surges Over 200 Points; Aaron's Shares Jump June 17, 2024 Via Benzinga Is the Stock Market Closed on Juneteenth 2024? June 17, 2024 Via InvestorPlace ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation June 17, 2024 Via InvestorPlace Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal June 17, 2024 Via InvestorPlace Why Is Ovid Therapeutics (OVID) Stock Down 69% Today? June 17, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Monday's Intraday Session June 17, 2024 Via Benzinga Crude Oil Rises 1%; Mustang Bio Shares Spike Higher June 17, 2024 Via Benzinga Exposures Fossil Fuels US Stocks Mixed; Dow Tumbles Over 100 Points June 17, 2024 Via Benzinga Topics Stocks Exposures US Equities What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? June 17, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
